Effects of transdermal testosterone gel or an aromatase inhibitor on serum concentration and pulsatility of growth hormone in older men with age-related low testosterone

Jenny Pena Dias, Johannes D. Veldhuis, Olga Carlson, Michelle Shardell, Chee W. Chia, Denise Melvin, Josephine M. Egan, Shehzad Basaria

Research output: Contribution to journalArticle

Abstract

Growth hormone is the major regulator of growth and body composition. Pulsatile GH secretion declines exponentially with age. Testosterone replacement is being increasingly offered to older men with age-related low testosterone. Testosterone administration has been shown to stimulate GH secretion. However, little is known about the effect of testosterone aromatization to estradiol on GH pulsatility and its impact on IGF-1 in older men. Objective This randomized controlled proof-of-concept trial investigated the relative effects of testosterone and estradiol on GH pulsatility and IGF-1 in older men with low testosterone. Design Thirty-seven men, ≥ 65 years with total testosterone < 350 ng/dL were randomized to 5 g transdermal testosterone gel (TT), 1 mg oral aromatase inhibitor (AI) or placebo daily for 12 months. Primary outcome was deconvolution and approximate entropy analyses of pulsatile including basal and entropic modes of secretion performed at baseline and 3 months. Secondary outcomes included IGF-1 evaluated at baseline, 3 and 6 months. Results At 3 months, mean GH and in IGF-1 were similar between the three groups. At 6 months, IGF-1 significantly increased by Δ 15.3 ± 10.3 ng/ml in the TT-group compared to placebo (P = 0.03). Both intervention groups significantly increased GH pulse frequency (TT-group, P = 0.04; AI-group, P = 0.05) compared to placebo. The GH secretory-burst mode (duration) significantly decreased in the TT-group (P = 0.0018) compared to placebo while it remained unchanged in the AI-group (P = 0.059). Conclusions In older men, testosterone increases GH pulse frequency while the aromatization to estradiol is involved in the rise of IGF-1 levels.

Original languageEnglish (US)
Pages (from-to)143-147
Number of pages5
JournalMetabolism: Clinical and Experimental
Volume69
DOIs
StatePublished - Apr 1 2017
Externally publishedYes

Fingerprint

Aromatase Inhibitors
Growth Hormone
Testosterone
Gels
Insulin-Like Growth Factor I
Serum
Placebos
Estradiol
Entropy
Body Composition

Keywords

  • Aromatase inhibitor
  • Growth hormone
  • Insulin-like growth factor-1
  • Testosterone replacement

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Effects of transdermal testosterone gel or an aromatase inhibitor on serum concentration and pulsatility of growth hormone in older men with age-related low testosterone. / Pena Dias, Jenny; Veldhuis, Johannes D.; Carlson, Olga; Shardell, Michelle; Chia, Chee W.; Melvin, Denise; Egan, Josephine M.; Basaria, Shehzad.

In: Metabolism: Clinical and Experimental, Vol. 69, 01.04.2017, p. 143-147.

Research output: Contribution to journalArticle

Pena Dias, Jenny ; Veldhuis, Johannes D. ; Carlson, Olga ; Shardell, Michelle ; Chia, Chee W. ; Melvin, Denise ; Egan, Josephine M. ; Basaria, Shehzad. / Effects of transdermal testosterone gel or an aromatase inhibitor on serum concentration and pulsatility of growth hormone in older men with age-related low testosterone. In: Metabolism: Clinical and Experimental. 2017 ; Vol. 69. pp. 143-147.
@article{a5caed14aa8241a48afd75c9d2e5e9a5,
title = "Effects of transdermal testosterone gel or an aromatase inhibitor on serum concentration and pulsatility of growth hormone in older men with age-related low testosterone",
abstract = "Growth hormone is the major regulator of growth and body composition. Pulsatile GH secretion declines exponentially with age. Testosterone replacement is being increasingly offered to older men with age-related low testosterone. Testosterone administration has been shown to stimulate GH secretion. However, little is known about the effect of testosterone aromatization to estradiol on GH pulsatility and its impact on IGF-1 in older men. Objective This randomized controlled proof-of-concept trial investigated the relative effects of testosterone and estradiol on GH pulsatility and IGF-1 in older men with low testosterone. Design Thirty-seven men, ≥ 65 years with total testosterone < 350 ng/dL were randomized to 5 g transdermal testosterone gel (TT), 1 mg oral aromatase inhibitor (AI) or placebo daily for 12 months. Primary outcome was deconvolution and approximate entropy analyses of pulsatile including basal and entropic modes of secretion performed at baseline and 3 months. Secondary outcomes included IGF-1 evaluated at baseline, 3 and 6 months. Results At 3 months, mean GH and in IGF-1 were similar between the three groups. At 6 months, IGF-1 significantly increased by Δ 15.3 ± 10.3 ng/ml in the TT-group compared to placebo (P = 0.03). Both intervention groups significantly increased GH pulse frequency (TT-group, P = 0.04; AI-group, P = 0.05) compared to placebo. The GH secretory-burst mode (duration) significantly decreased in the TT-group (P = 0.0018) compared to placebo while it remained unchanged in the AI-group (P = 0.059). Conclusions In older men, testosterone increases GH pulse frequency while the aromatization to estradiol is involved in the rise of IGF-1 levels.",
keywords = "Aromatase inhibitor, Growth hormone, Insulin-like growth factor-1, Testosterone replacement",
author = "{Pena Dias}, Jenny and Veldhuis, {Johannes D.} and Olga Carlson and Michelle Shardell and Chia, {Chee W.} and Denise Melvin and Egan, {Josephine M.} and Shehzad Basaria",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.metabol.2017.01.025",
language = "English (US)",
volume = "69",
pages = "143--147",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Effects of transdermal testosterone gel or an aromatase inhibitor on serum concentration and pulsatility of growth hormone in older men with age-related low testosterone

AU - Pena Dias, Jenny

AU - Veldhuis, Johannes D.

AU - Carlson, Olga

AU - Shardell, Michelle

AU - Chia, Chee W.

AU - Melvin, Denise

AU - Egan, Josephine M.

AU - Basaria, Shehzad

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Growth hormone is the major regulator of growth and body composition. Pulsatile GH secretion declines exponentially with age. Testosterone replacement is being increasingly offered to older men with age-related low testosterone. Testosterone administration has been shown to stimulate GH secretion. However, little is known about the effect of testosterone aromatization to estradiol on GH pulsatility and its impact on IGF-1 in older men. Objective This randomized controlled proof-of-concept trial investigated the relative effects of testosterone and estradiol on GH pulsatility and IGF-1 in older men with low testosterone. Design Thirty-seven men, ≥ 65 years with total testosterone < 350 ng/dL were randomized to 5 g transdermal testosterone gel (TT), 1 mg oral aromatase inhibitor (AI) or placebo daily for 12 months. Primary outcome was deconvolution and approximate entropy analyses of pulsatile including basal and entropic modes of secretion performed at baseline and 3 months. Secondary outcomes included IGF-1 evaluated at baseline, 3 and 6 months. Results At 3 months, mean GH and in IGF-1 were similar between the three groups. At 6 months, IGF-1 significantly increased by Δ 15.3 ± 10.3 ng/ml in the TT-group compared to placebo (P = 0.03). Both intervention groups significantly increased GH pulse frequency (TT-group, P = 0.04; AI-group, P = 0.05) compared to placebo. The GH secretory-burst mode (duration) significantly decreased in the TT-group (P = 0.0018) compared to placebo while it remained unchanged in the AI-group (P = 0.059). Conclusions In older men, testosterone increases GH pulse frequency while the aromatization to estradiol is involved in the rise of IGF-1 levels.

AB - Growth hormone is the major regulator of growth and body composition. Pulsatile GH secretion declines exponentially with age. Testosterone replacement is being increasingly offered to older men with age-related low testosterone. Testosterone administration has been shown to stimulate GH secretion. However, little is known about the effect of testosterone aromatization to estradiol on GH pulsatility and its impact on IGF-1 in older men. Objective This randomized controlled proof-of-concept trial investigated the relative effects of testosterone and estradiol on GH pulsatility and IGF-1 in older men with low testosterone. Design Thirty-seven men, ≥ 65 years with total testosterone < 350 ng/dL were randomized to 5 g transdermal testosterone gel (TT), 1 mg oral aromatase inhibitor (AI) or placebo daily for 12 months. Primary outcome was deconvolution and approximate entropy analyses of pulsatile including basal and entropic modes of secretion performed at baseline and 3 months. Secondary outcomes included IGF-1 evaluated at baseline, 3 and 6 months. Results At 3 months, mean GH and in IGF-1 were similar between the three groups. At 6 months, IGF-1 significantly increased by Δ 15.3 ± 10.3 ng/ml in the TT-group compared to placebo (P = 0.03). Both intervention groups significantly increased GH pulse frequency (TT-group, P = 0.04; AI-group, P = 0.05) compared to placebo. The GH secretory-burst mode (duration) significantly decreased in the TT-group (P = 0.0018) compared to placebo while it remained unchanged in the AI-group (P = 0.059). Conclusions In older men, testosterone increases GH pulse frequency while the aromatization to estradiol is involved in the rise of IGF-1 levels.

KW - Aromatase inhibitor

KW - Growth hormone

KW - Insulin-like growth factor-1

KW - Testosterone replacement

UR - http://www.scopus.com/inward/record.url?scp=85011045321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011045321&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2017.01.025

DO - 10.1016/j.metabol.2017.01.025

M3 - Article

C2 - 28285644

AN - SCOPUS:85011045321

VL - 69

SP - 143

EP - 147

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

ER -